DaVita Announces Clinical Study Results for X9 System
DaVita, as an investor, reported successful clinical study results for the investigational X9 System, a device designed to assist with needle placement during hemodialysis.
Stocks · News reference
Shares of dialysis services and equipment companies are trading lower after reports suggesting that the Trump administration is preparing a new kidney care plan that stresses market competition and preventative care, which may contain risk for current business models.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
DaVita Portfolio Company X9 Receives FDA Breakthrough Device Designation
DaVita, an investor in medical technology company X9, Inc., acknowledged the FDA's Breakthrough Device Designation for X9's ultrasound system designed for hemodialysis vascular access.
Pomerantz LLP Investigates Securities Fraud Claims Against DaVita Inc.
Pomerantz LLP has announced an investigation into DaVita Inc. regarding potential securities fraud or unlawful business practices following a recent federal strategy announcement concerning the dialysis market.
DaVita Responds to HHS Kidney Care National Plan
DaVita issued a response to the U.S. Department of Health and Human Services (HHS) regarding the national kidney care plan, reaffirming its commitment to innovation, patient access, and choice.
Fresenius Medical Care Announces Share Buyback Progress
Fresenius Medical Care AG reported the acquisition of 111,000 shares as part of its ongoing share buyback program.
JPMorgan Maintains Underweight Rating on Fresenius Medical Care
JPMorgan Chase & Co. has maintained its 'Underweight' rating on Fresenius Medical Care, citing concerns over consensus estimates and potential headwinds from US reimbursement costs.